Patients
Nine patients diagnosed with relapsed non-M3 AML were treated with
fludarabine and busulfan at the Blood and bone Marrow Transplantation
center in Taleqani hospital (Tehran, Iran) between 2019 and 2022 were
joined in this study. All patients signed informed consent before
entering the study, and the advantage of their admission was explained
verbally and in writing. All procedures in the present study were
performed following the relevant guidelines and regulations of the Royan
Institute and approved by the Institutional Review Board and Ethics
Committee of the Royan Institute, Tehran, Iran (approval no.
IR.ACECR.ROYAN.REC.1400.055). The main biological characteristics of the
patients are in Table 1.